Eggschain CEO to Speak on Blockchain Applications in Fertility Treatment at 2022 College of Reproductive Biology Symposium – Yahoo Finance

Event hosted by the American Association of Bioanalysts

AUSTIN, Texas, April 14, 2022--(BUSINESS WIRE)--Eggschain, the first biotech company on the bitcoin blockchain and the first patented blockchain-integrated chain of custody and end-to-end lab management solution for all biospecimens, is pleased to share that company founder and CEO Wei Escala will be speaking at the 2022 College of Reproductive Biology (CRB) Symposium. The event will take place May 12 May 14 in Austin, Texas, at the AT&T Hotel and Conference Center.

Details of Ms. Escalas discussion are below: Title: Blockchain and Information Technology Applications in Fertility Treatment Date: Saturday, May 14, 2022 Time: 10:15 a.m. - 11:15 a.m. CT

"The CRB Symposium presents an excellent opportunity to educate the scientific community on how our platform can bring professional grade information and data to individuals undergoing fertility treatments in a secure, transparent and universally trackable format, as well as how our platform can apply to other biospecimen procedures," said Wei Escala, founder and CEO of Eggschain. "Biospecimens include but are not limited to sperm, eggs, embryos, DNA, RNA, tissues, organs, genome, blood and stem cells, illustrating the broad application of Eggschains patented capabilities."

The College of Reproductive Biology (CRB), a not-for-profit special interest group of the American Association of Bioanalysts (AAB), provides a focused forum for andrologists and embryologists to communicate with each other, share ideas and knowledge, and foster closer collaborations. CRBs educational programs have been well received within the field of assisted reproductive technology by clinic staff and laboratory personnel. The CRB Symposium educational program features a variety of topics covering the newest science and technology and is approved for continuing education credit. Symposium attendees are reproductive biologists and include laboratory directors, technical supervisors, clinical consultants, and andrology and embryology laboratory scientists.

Story continues

About Eggschain, INC.Eggschain is a healthcare technology company and thought leader in the fertility, health tech, family-building and cryogenic preservation industries. Patent-granted and cloud-based, Eggschain is the first blockchain-integrated inventory management and chain of custody technology for tracking bio specimens, including sperm, eggs, embryos, genome, stem cell, tissues and organs, and other genetic material. In partnership with several of the worlds leading experts in reproductive biology, endocrinology and high complexity labs, Eggschain delivers medical grade information and data to individuals undergoing IVF in a secure, transparent and universally trackable format and also provides the means for clinics to monitor their inventory, either personal, such as oocytes and sperm, or lab-related, including equipment inventory and maintenance scheduling. At its core, Eggschain strives to enable better decision-making, preserving the hope of life and helping to advance humanity.

About AABThe American Association of Bioanalysts (AAB) is a professional association representing bioanalysts (clinical laboratory directors, owners, managers, and supervisors), medical technologists, medical laboratory technicians, and physician office laboratory technicians. AABs specialized membership sections include the College of Reproductive Biology (CRB), AAB Associate Member Section (AMS), Environmental Biology and Public Health (EBPH) Section, and the National Independent Laboratory Association (NILA).

View source version on businesswire.com: https://www.businesswire.com/news/home/20220414005145/en/

Contacts

Caroline Cunningham, Porter Novelli caroline.cunningham@porternovelli.com 203.969.4308

Original post:
Eggschain CEO to Speak on Blockchain Applications in Fertility Treatment at 2022 College of Reproductive Biology Symposium - Yahoo Finance

Unproved Stem Cell Clinics Proliferate in the U.S …

Patients seeking stem cell therapies for achy joints or shoulder injuries no longer need to hop a plane to Mexico or China. More than 550 clinics around the U.S. offer unproved interventions for sports injuries and conditions including autism, multiple sclerosis and Alzheimers disease. In cities like Beverly Hills or New York a prospective patient may only need to drive some 20 or 30 minutes from the center of town to find such a treatment.

This vast stem cell market has boomed in recent years, particularly for orthopedic applications such as easing joint pain or for facelifts and other cosmetic procedures. In one frequently advertised regimen a patient might have adult stem cells harvested from his own fat tissue and injected at an injury site, purportedly to speed recovery. Professional athletes including football stars Peyton Manning and Chris Johnson have reportedly used stem cell injections to help them get back onto the field.

Yet there is a darker side to the promise of these treatments. There is little systematic data about patients long-term outcomespositive or negativeand in most cases there is no scientific evidence that these costly procedures work. Many of these cellular therapies may not do much of anything but there is also the serious risk that recipients of cell injections could develop serious complications including blood clots or dangerous immune reactions, says Paul Knoepfler, a stem cell researcher at the University of California, Davis, School of Medicine and co-author of a new analysis, published Thursday in Cell Stem Cell.*

One U.S. patient traveled to China, Mexico and Argentina for stem cell therapies following a stroke and went on to develop a huge mass in his lower spinereplete with someone elses cells, according to a recent account in The New England Journal of Medicine. Without clear evidence that these procedures are safe, effective and actually tap the type of cells they claim to use, they should be avoided, Knoepfler says. (Bone marrow stem cell therapies used for cancer and blood disorder treatments, however, are widely accepted medical procedures.)

Armed with new data about the proliferation of stem cell clinics, Knoepfler and co-author, University of Minnesota bioethicist Leigh Turner, are seeking to correct the widespread belief that such procedures only happen overseas: Patients wishing to engage in stem cell tourism need only drive minutes from metropolitan areas across the U.S., not to a foreign country, they note.

Such clinics have often sidestepped heavy regulatory scrutiny, claiming they are eligible for a U.S. Food and Drug Administration exemption that applies to minimally manipulated cells. Some claim to extract a patients cells found in fat, bones or other tissues and inject them back into the same patient at a different sitesuch as a joint or a saggy chinwithin the same operation, all without substantially altering the cells. But many of these clinics also offer myriad types of stem cell treatment that would suggest they are not compliant with federal regulations, the authors wrote.

Amid this stem cell therapy explosion, the FDA recently issued draft guidance that would clarify and tighten its regulation of this area. The FDA is concerned that the hope patients have for treatments not yet proven to be safe and effective may leave them vulnerable to unscrupulous providers of stem cell treatments that are illegal and potentially harmful, FDA spokesperson Andrea Fischer said in a statement. If the proposed guidelines are enacted, the FDA would likely bring more of these clinics under its purview and regulate offerings in the same way as biological drugs. Public interest in this contentious area is undeniable: The FDA is holding a delayed public hearing on stem cell regulation this fall, after it was overwhelmed by audience sign-ups for its scheduled hearing in April.

This all should still be in the research phase without question, says Peter Rubin, a stem cell researcher who chairs the Department of Plastic Surgery at the University of Pittsburgh Medical Center and runs a clinical trial to test the use of stem cells to repair severe facial wounds and limb injuries in soldiers. We need to establish credible data around these therapies before bringing them to patients, he adds. Rubin, who was not involved in Knoepfler and Turners latest research, plans to testify at the hearing this fall.

Currently, hundreds of U.S. clinics61 percent of the businesses in the new analysismarket therapies that use fat stem cells. Although details vary between clinics, that often means the clinic gives a patient liposuction then chemically separates stem cells from the fat and centrifuges them before injecting them into an injury site to purportedly help a patient heal faster or to alleviate pain. Fat is a structural tissue, and if you break down its biological properties so it can no longer provide padding or cushioning, then it has been manipulated, Rubin says. Such procedures, he says, would likely require FDA regulation under the new proposed guidelines.

To get a new count showing exactly how widespread stem cell clinics have become, Knoepfler and Turner scoured the internet for Web sites marketing stem cell interventions. They found 351 U.S. businesses engaged in direct-to-consumer marketing of such services offered at 570 clinics. Most of the clinics were concentrated in California, Florida, Texas, Colorado, Arizona and New York, but most states had at least one. There were also certain hot spot cities with a dozen or more clinics such as Beverly Hills, New York, San Antonio and Los Angeles. The authors could not verify that the clinics truly offer what is advertised on their Web sites, the sources of their stem cells or their interactions with the FDA.

Yet what they did find, Knoepfler says, was very concerningparticularly because some of the ads targeted conditions that affect particularly vulnerable populations, including children. Nine clinics promoted stem cell treatments for autism and cerebral palsy and another 33 advertised therapies for muscular dystrophy, a disease that primarily afflicts kids. Alzheimers disease treatments were offered by 27 clinics. These are the conditions that most concern me because there is the most striking gap between the marketing claims being made and the actual evidence that is available, Turner says. In effect [the patients] are participants in unapproved human-subjects research without even realizing it.

*Editor's Note (7/11/16): This sentence was edited after posting to clarify information about the authorship of the study.

Read the rest here:
Unproved Stem Cell Clinics Proliferate in the U.S ...

Eggschain, Pioneering Chain of Custody Solution for Fertility Treatments and Other Biospecimens, Officially First Healthcare Biotech on Bitcoin…

AUSTIN, Texas--(BUSINESS WIRE)--Eggschain, the pioneering authority in blockchain-based digital chain of custody tracking of blood, genome, tissues, organs, DNA, RNA, sperm, eggs, embryos, and other biospecimens, is making history again.

On November 24th, 2021, Eggschain founder and CEO Wei Escala made history by storing her eggs on the blockchain, doing so through the platform she created. Working with Dr. Hugh Taylor, Chair of Obstetrics, Gynecology and Reproductive Sciences at Yale School of Medicine, his team of physicians and nurses, as well as the Eggschain team, Wei underwent egg retrieval on the 24th of November. She entered her data through the Eggschain platform and broadcasted to the blockchain, once Yale School of Medicine verified the accuracy of the data on the same day through the platform.

This is an exciting milestone for the field of fertility preservation, said Dr. Taylor. A reliable and confidential tracking system will allow us to assure the safety and quality of frozen reproductive tissue. Eggschain enables greater transparency and security for patients and health professionals.

Earlier this month, Eggschain successfully generated a bitcoin cryptographic block hash, becoming the first biotech healthcare company on the mainnet. The first patented supply chain system that combines blockchain and genetics to bring secure, transparent, and professional grade information and data to individuals undergoing IVF. Eggschain was developed on Stacks, a collection of independent entities, developers, and community members working to build a user-owned internet on Bitcoin.

Eggschain will mark these dual milestones with an NFT drop that celebrates the arrival of Babies on the Blockchain. The first NFT, Into the Light, shows the meeting of sperm and egg as a light projection on a dark sky, an evocative illustration of the art and science of IVF and the potential for future life. Eggschain will open a whitelist with 2,000 spots in early 2022, with approximately 2,500 to 10,000 NFTs to be released.

Fertility treatment is emotionally and physically demanding, often creating stress and a sense of isolation along the way, said Ms. Escala. By sharing my Eggschain experience, I hope to begin to build a sense of community that help others undergoing fertility treatments feel less alone and more empowered. By delivering medical grade information in a secure and universally trackable format, Eggschain provides transparency and peace of mind, holding the potential to forever change that dynamic for the better.

For further information about Eggschain, please visit https://eggschain.com/.

About Eggschain, INC.

Eggschain is a healthcare technology company and thought leader in the fertility, health tech, family-building and cryogenic preservation industries. Patent-granted and cloud-based, Eggschain is the first blockchain-integrated inventory management and chain of custody technology for tracking biospecimens, including sperm, eggs, embryos, genome, stem cell, tissues and organs, and other genetic material. In partnership with several of the worlds leading experts in reproductive biology, endocrinology and high complexity labs, Eggschain delivers medical grade information and data to individuals undergoing IVF in a secure, transparent and universally trackable format and also provides the means for clinics to monitor their inventory, either personal, such as oocytes and sperm, or lab-related, including equipment inventory and maintenance scheduling. At its core, Eggschain strives to enable better decision-making, preserving the hope of life and helping to advance humanity.

About Stacks

Secure smart contracts and apps for Bitcoin. The Stacks ecosystem is a collection of independent entities, developers, and community members working to build a user-owned internet on Bitcoin. The Stacks 2.0 blockchain extends the design of Bitcoin to enable secure apps and predictable Clarity smart contracts without modifying Bitcoin itself, opening innovation on the network for the first time. The Stacks cryptocurrency (STX) is used as fuel for networking activity and contract execution and can be locked by STX holders via Stacking to earn Bitcoin (BTC) rewards for supporting blockchain consensus. Stacks cryptocurrency was distributed to the general public through the first-ever SEC qualified token offering in U.S. history.

The rest is here:
Eggschain, Pioneering Chain of Custody Solution for Fertility Treatments and Other Biospecimens, Officially First Healthcare Biotech on Bitcoin...

Select residents with high-risk health issues will start getting a booster shot starting tomorrow – Newstalk 610 CKTB (iHeartRadio)

Select residents with high-risk health issues will start getting a booster shot starting tomorrow.

Niagara Health will be administering the shot to those with eligibility letters from their doctor.

High-risk populations: - Transplant recipients (including solid organ transplant and hematopoietic stem cell transplants) - Patients with hematological cancers (examples include lymphoma, myeloma, leukemia) on active treatment (chemotherapy, targeted therapies, immunotherapy) for malignant hematologic disorders - Recipients of an anti-CD20 agent (e.g. rituximab, ocrelizumab, ofatumumab) - Residents of high-risk congregate settings including long-term care homes, higher-risk licensed retirement homes and First Nations Elder Care Lodges

Eligibility letters are required for third doses and must include: - Dated and on letterhead - Contact information for physician, specialist or medical practice of individual completing the form - Patient's name (typed/generic letters will not be accepted) - List of specific criteria required for patient eligibility - Patient's eligible condition for third dose

Niagara Health will administer third COVID-19 vaccine doses starting Tuesday, Aug. 31 at our St. Catharines Site as walk-in only between 8 a.m. and 3 p.m. (closed between 12 and 1 p.m.) on a first-come, first-served basis.

Transplant recipients, patients with hematological cancers on active treatments and recipients of an anti-CD20 agent can receive their third dose at a minimum of eight weeks (56 days) following their second dose and will be contacted directly by their health care provider, such as their primary care provider, specialist or hospital specialty program.

Third doses will be offered to residents of long-term care homes and provincially-designated high-risk retirement homes at a minimum of five months following their second dose and will be co-ordinated through Public Health. Eligible high-risk populations with eligibility letters can also receive their third dose at any Niagara Region Public Health vaccination clinics.

For more information, please visit https://www.niagarahealth.on.ca/site/vaccination-clinic

Read more here:
Select residents with high-risk health issues will start getting a booster shot starting tomorrow - Newstalk 610 CKTB (iHeartRadio)

Princeton To Offer Third Dose Of COVID-19 Vaccine In September – Reverb MSN Music

Shutterstock

PRINCETON, NJ Beginning Sept. 20, the Princeton Health Department will offer booster doses to those who have had the Pfizer or Moderna COVID-19 vaccine for eight months, the department announced.

Princeton Health Department is expected to begin hosting regular booster clinics starting in September. More information on the details of these clinics will be released shortly, the department said in the newsletter.

A third vaccine dose for immunocompromised individuals is now available in the Garden State, a shot "intended to ensure that [immunocompromised people] have enough protection against COVID because they may not build up the same level of immunity as other people," said New Jersey Department of Health Commissioner Judy Persichilli during a Monday afternoon news conference.

Earlier in August, President Joe Biden announced that booster shots will be available starting Sept. 20. The FDA and the CDC have already authorized the third dose of either Pfizer or Modera COVID-19 vaccines for those who are moderate to severely immunocompromised.

Read more: COVID-19 Booster Shot Authorized For Immunocompromised

The plan is for a booster shot to eventually become available to all adults eight months after their second shot. The booster shot is free and does not require proof of ID or health insurance.

Those in active cancer treatment, those with uncontrolled HIV, organ or stem cell transplant recipients, those taking medications that weaken their immune systems such as chemotherapy or anti-rejection medication after a transplant, and disease-modifying antirheumatic drugs are currently eligible for a third dose. A full list of conditions can be found on the CDC website.

The state is currently determining point-of-distribution locations for the third dose in each county. Third dose mega-sites may also be in the cards, Persichilli added, noting that the state is prepared for a "range of scenarios."

Meanwhile, Mercer County is offering walk-in COVID-19 vaccine clinics for the unvaccinated. Here are the upcoming clinics:

Princeton Health Department Clinic

Princeton University Clinics (located in Jadwin Gym)

Mercer County Pop-Up Clinics

(With reporting from Nicole Rosenthal, Patch Staff)

Thank you for reading. Have a correction or news tip? Email sarah.salvadore@patch.com

Get breaking news alerts on your phone with our app. Download here. Sign up to get Patch emails so you don't miss out on local and statewide news.

Visit link:
Princeton To Offer Third Dose Of COVID-19 Vaccine In September - Reverb MSN Music

A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems – On Cancer – Memorial Sloan Kettering

As you may have heard, the Centers for Disease Control and Prevention (CDC)has recommended a third dose of the COVID-19 vaccine for people who are immunocompromised. This includes some but not all people with cancer.

Mini Kamboj

Mini Kamboj, Memorial Sloan Kettering Cancer CentersChief Medical Epidemiologist, has answers to your questions about who is eligible and how you can schedule an appointment to receive your third shot.

For a vaccine to protect you, it must activate your immune system. In some immunocompromised patients, this ability is impaired, so a third dose can boost the immune response.

According to the CDC, among severely immunocompromised people who had undergone solid organ transplant and had virtually no protection after receiving two doses of the Pfizer-BioNTech or Moderna vaccine, 30 to 50% developed antibodies protecting them from COVID-19 after getting an additional dose.

People who have moderate to severe immunosuppression qualify to receive an additional dose, usually because of an organ or stem cell transplant, HIV infection, steroid therapy, or certain cancer treatments that impair the bodys ability to fight infections.

Its important to know that not all cancer patients have a weakened immune system. Those cancer patients who are considered immunocompromised include:

These eligibility criteria cover the most common indications. Your provider will be able to order the third vaccine dose for other immunosuppressive treatments or conditions if they decide that the extra dose will benefit you.

If you meet the criteria, you can receive a third dose 28 days or later after completing your first vaccine series.

Only patients who completed their primary immunization with either Pfizer-BioNTech or Moderna vaccines can receive the third dose. MSK will offer the same vaccine brand to patients as they previously received. Mixing vaccines is not permitted at this time.

The CDC has not made any recommendations yet for people who received the Johnson & Johnson vaccine. We are closely following their guidance and will communicate any changes.

To find out if you should get a third dose, call your MSK doctors office or send a message through the MyMSK patient portal. If you are eligible for an additional vaccine, your doctor will schedule an appointment for you.

On Wednesday, August 18, MSK will begin offering the additional vaccines at the David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, located at 530 East 74th Street.

Starting Monday, August 23, we will be scheduling appointments at:

These clinics will be open 9:00 a.m. to 5:00 p.m., Monday through Friday.

Additional dates and locations, including our New Jersey locations, will be added shortly.

If you think you meet the criteria for getting a thirdvaccine dose, you should call your providers office to confirm your eligibility, and a vaccine appointment will be scheduled for you. You should be prepared to share your vaccination card or a photo of it. Please present information from your card, rather than the Excelsior pass, which does not have the details about what vaccine brand you received and on what dates.

Yes, the Food and Drug Administration (FDA) hasgranted emergency use authorization for patients 12 and older to receive the Pfizer-BioNTech vaccine and 18 and older to receive the Moderna vaccine.

The side effects from a third COVID-19 vaccine are similar to those experienced after receiving the original vaccines. Scientists in Israel recently began giving a third dose of the Pfizer-BioNTech vaccine to people with compromised immune systems. Side effects were reported by 31% of people, the most common being soreness at the injection site. Other side effects included fatigue, headache, body aches, and fever. These symptoms dont last long about one to three days.

The safety of a third dose in people whove had COVID-19 breakthrough infections is not known, therefore an additional dose for those patients is not recommended at this time. Some patients in whom initial vaccine responses are expected to be severely blunted, such as stem cell transplant orCAR-T recipients or those treated with B-cell depleting therapies, may benefit from a third dose after breakthrough infection. Discuss your situation with your clinical care team.

Even after the third dose, people with weakened immune system must take precautions to protect themselves from COVID-19. You should:

If you develop symptoms of COVID-19, contact your clinical care team and get tested.

Not at this time.The vaccines remain very effective against severe disease for those who do not have compromised immune systems. In the future, third doses may be recommended for more people because immune protection tends to weaken over time. In addition, as new variants of COVID-19 emerge, it may be necessary to design new vaccines to protect against them.

August 16, 2021

Read the rest here:
A Third Dose of the COVID-19 Vaccine Recommended for Some Cancer Patients With Weakened Immune Systems - On Cancer - Memorial Sloan Kettering

Exclusive Report on Stem Cell Therapy in Cancer Market | Analysis and Opportunity Assessment from 2021-2028 |Aelan Cell Technologies, Baylx, Benitec…

The Stem Cell Therapy in Cancer Market 2021-2028 exploration report by Infinity Business Insights offers an inside and out assessment dependent on Leading Players, Development, Project Economics, Future Growth, Market Estimate, Pricing Analysis, and Revenue.

Rising interests in the structure of a proficient medication dealing with the anchor are projected to give the global Stem Cell Therapy in Cancer market a significant lift in the coming years. Another factor projected to upgrade the global Stem Cell Therapy in Cancer market over the gauge time frame is an expansion in the use of different medication wellbeing programs related to other designing controls.

Get SAMPLE Pages of report @

https://www.infinitybusinessinsights.com/request_sample.php?id=488299

PRIME 30+ players of the Stem Cell Therapy in Cancer Industry:

Aelan Cell Technologies, Baylx, Benitec Biopharma, Bluerock Therapeutics, Calidi Biotherapeutics, Cellular Dynamics International, Center For Ips Cell Research And Application, Century Therapeutics, Khloris Biosciences, Reneuron, & Others.

The pandemic has impacted the worldwide medical services in the Stem Cell Therapy in Cancer market, and nations, for example, Germany and the United States have encountered huge issues. To close the hole in the inventory network, the public authority is putting resources into medical services innovation to satisfy the rising need.

Stem Cell Therapy in Cancer industry -By Application:Hospitals, Specialized Clinics, Academic & Research Institutes, Others,

Stem Cell Therapy in Cancer industry By Product:

Stem Cell And Non-Stem Cell

Contact Us: Amit Jain Sales Co-Ordinator International: +1 518 300 3575 Email: inquiry@infinitybusinessinsights.com Website: https://www.infinitybusinessinsights.com Facebook: https://facebook.com/Infinity-Business-Insights-352172809160429 LinkedIn: https://www.linkedin.com/company/infinity-business-insights/ Twitter: https://twitter.com/IBInsightsLLP

Read more here:
Exclusive Report on Stem Cell Therapy in Cancer Market | Analysis and Opportunity Assessment from 2021-2028 |Aelan Cell Technologies, Baylx, Benitec...

Global Cell Therapy Bioprocessing Market Scope and Forecast By 2021-2027 I Top key players- Fresenius Kabi SA, Asahi Kasei Corporation, The Manomet…

The global Cell Therapy Bioprocessing Market is segmented on the basis of type, Application, End-User, and Region. The Cell Therapy Bioprocessing Market accounted for xx% in 2020 and is forecasted to account for a CAGR of xx% in the forecast period of 2021-27.

Get a Sample Copy of the Report to understand the structure of the complete report https://www.infinitybusinessinsights.com/request_sample.php?id=607920

The COVID-19 crisis has expanded its horizons. Cell Therapy Bioprocessing Market already perform an important, if underappreciated, role in the healthcare system around the world. It has made healthcare available to those who are relocated or isolated. During the ongoing COVID-19 outbreak, mobile hospitals were a lifesaver for those who didnt have easy access to hospitals. The utilization of mobile hospitals and associated applications, according to healthcare specialists and health IT developers, might considerably aid in monitoring and regulating the COVID-19 outbreak.

The global Cell Therapy Bioprocessing Market industry is being driven by an increase in the prevalence of infectious and chronic diseases. In times of pandemic, mobile hospitals have proven their importance, from cost-cutting benefits for the healthcare system to efficient patient treatment in less time. Furthermore, new medical gadgets and imaging technology are increasingly being used to diagnose patients as early as feasible.

Top key players: Fresenius Kabi SA, Asahi Kasei Corporation, Sartorius SA, MERCK KGaA, THERMO FISHER SCIENTIFIQUE INC., Corning incorporated, Cytiva, Lonza, Repligen, and Catalent Inc

Segmentation: Biotreatments market by technology by cell therapy: Bioreactor Freeze Electrospinning Control flow centrifugation Ultrasonic Lysis genome editing technology cellular immortalization technology Technology viral vectors

Cell therapy bioprocessing market by cell type: Stem cell Immune cell Human embryonic stem cell Pluripotent stem cell Hematopoietic stem cell

Cell therapy biotreatment market by indication: Cardiovascular disease (CVD) Oncology Wound healing Orthopedic Others

Cell therapy bioprocessing market by end user: Hospitals and clinics Diagnostic centers Regenerative medicine centers University and research institute

Our industry experts are working determinedly to comprehend, amass and opportune convey appraisal on effect of COVID-19 debacle on numerous organizations and their customers to help them in taking brilliant business choices.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Cell Therapy Bioprocessing Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Get Up to 20% Discount on this Premium Report https://www.infinitybusinessinsights.com/request_sample.php?id=607920

Geographically, global Cell Therapy Bioprocessing Market has been scrutinized across global regions to study about various successful strategies carried out by industries. It includes major regions such as North America, Latin America, Middle East, Asia-Pacific, Africa, and Europe on the basis of different parameters. Different top-level industries have been profiled to get better insights into the global Cell Therapy Bioprocessing Market. Additionally, it offers detailed elaboration on different policies, rules and regulations initiated by governments to set standards for global market businesses.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before Infinity Business Insights curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

If you need anything more than these then let us know and we will prepare the report according to your requirement.

Contact Us: Amit J Sales Co-Ordinator International : +1 518 300 3575 Website: inquiry@infinitybusinessinsights.com

Website: https://www.infinitybusinessinsights.com

Social Links:

Facebook: https://facebook.com/Infinity-Business-Insights-352172809160429

LinkedIn: https://www.linkedin.com/company/infinity-business-insights

Twitter: https://twitter.com/IBInsightsLLP/

Read more:
Global Cell Therapy Bioprocessing Market Scope and Forecast By 2021-2027 I Top key players- Fresenius Kabi SA, Asahi Kasei Corporation, The Manomet...

The Oncology Institute of Hope and Innovation (TOI) Expands to San Diego County – Yahoo Finance

Two state-of-the-art clinics opening in Vista and Chula Vista with a third in Hillcrest slated for later this year

SAN DIEGO, August 04, 2021--(BUSINESS WIRE)--The Oncology Institute of Hope and Innovation (TOI) began seeing patients this week at two new locations in Vista and Chula Vista, marking the community-based oncology providers entry into San Diego County. A third location in Hillcrest is slated to open in the fall.

Founded in 2007, TOI is a multi-state cancer care practice dedicated to healing and empowering patients through compassion, innovation, and state-of-the-art medical care. TOI is the largest value-based oncology practice in the U.S., taking accountability for both the quality outcomes as well as the medical costs associated with a population of more than 1 million patients. TOI recently announced its intent to become a publicly traded company via a business combination with DFP Healthcare (NASDAQ: DFPH, DFPHW).

"At TOI, we believe every patient should have access to specialized care including clinical trials and transfusions, in their own community," shared Brad Hively, CEO. "We are thrilled to bring our cutting-edge cancer care to San Diego County."

As the nations leading value-based oncology provider, TOI offers a diverse set of cutting-edge resources including:

A leading clinical research program offering patients access to more than 130 clinical trials.

Comprehensive dispensary services to offer convenience and savings to patients receiving oral chemotherapeutics.

A care management program which helps patients navigate a complex healthcare system.

A state-of-the-art website with educational resources, scheduling capabilities, and a convenient patient portal.

Patients can now book appointments with three highly rated physicians: Drs. Jeffrey Andrey, Babak Baseri, and Anwer Shaikh.

About The Oncology Institute of Hope and Innovation

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is one of the largest community oncology practices in the US as well as our nations leading value-based oncology services platform. TOI employs 70+ physicians and advanced practice providers in 45+ clinic locations, with more than 500 total employees helping to offer leading-edge, evidence-based cancer care to a population of more than 1 million patients. TOI brings comprehensive, integrated cancer care into community settings, including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced tertiary care settings. For more information visit http://www.theoncologyinstitute.com.

Story continues

View source version on businesswire.com: https://www.businesswire.com/news/home/20210804005725/en/

Contacts

Julie Korinke Director, Marketing and Communications 562.735.3226 x.88806 juliekorinke@theoncologyinstitute.com

See the rest here:
The Oncology Institute of Hope and Innovation (TOI) Expands to San Diego County - Yahoo Finance

Covid-19 and the blood – Trinidad & Tobago Express Newspapers

PERSONS with haematological (blood) diseases are among those most at risk of severe illness and complications from Covid-19, says Trinidad-born, UK-based consultant haematologist and clinical senior lecturer Dr Keith Wilson.

Blood diseases are conditions that impact the bloods ability to function correctly. They can affect any of the three main components of blood.

Our bodies naturally respond to any infection by raising an immune response however people with haematological conditions have an impaired immune system either due to the condition itself or the treatment of the condition.

Most patients with haematological malignancies are immunosuppressed as a result of their baseline condition, treating such ones with chemo or radiotherapy will cause immunosuppression so you have immunosuppression upon immunosuppression. That would explain why those patients are at high risk of infection,says Wilson who is the Director of the South Wales Blood and Marrow Transplant Programme.

In a zoom interview with the Express, the haematologist also referred to preliminary results from recent studies in the UK which have revealed that people with haematological malignancies respond poorly to the vaccine. The studies show that even if such ones have been vaccinated their bodies may not mount an adequate response should they come into contact with the virus. Nevertheless, Wilson stresses that such highly vulnerable persons should take the vaccine.

Our advice to our patients is that they should be vaccinated. But that advice comes with a caveatwe cannot guarantee that they would respond adequately to the vaccine. So the advice is a double barrel oneget the vaccine but continue the protective measures that we have instituted over the years,he says.

Since the start of the pandemic, Wilson has been working longer hours. He and his colleagues had to change the way they work in a variety of settings. Their patients are vulnerable at the best of times so in order to protect them, Wilson and his department had to institute different zones in the hospital. Maintaining the zonal arrangement meant spacing out appointments and spacing patients out physically.

To get through the workload meant working for much longer periods than we were accustomed to and that has continued until now. The UK is experiencing its third wave and therefore the protective measures have to remain in place, those requirements havent been modified since we adopted them in March/April 2020, says Wilson.

The haematology unit also introduced telephone clinics for patients who do not need to be seen face to face.

Over the years, Wilsons hard work and dedication to his profession has won him recognition. In 2017 he was awarded Health Care Professional of the Year and was praised for being an extremely hard working individual with extremely high standards. He was also commended for supporting patients throughout their journey and being open and honest about their treatment options.

His commitment to improving treatment for patients came to the fore in the late 90s when Wilson and his colleagues at the South Wales Blood and Marrow Transplant Programme conducted a collaborative study on a method of transplantation called reduced intensity allogeneic stem cell transplantation. Stem cell transplantation has been around for decades however in the beginning the results were uniformly poor. Generally people received high doses of chemotherapy with radiation therapy, which meant that patients had to be young enough to tolerate the treatment, however patients who bore the greatest burden of the diseasepatients 60 years and olderwere excluded from these therapies, explained Wilson. During the collaborative study Wilson and his colleagues observed that the stem cells used in allogeneic or donor transplants actually have anti-leukaemic potential, much the same way the immune system can detect a cancer cell as foreign and attack it the same way it fights infection. That opened up the possibility of reducing the dose of chemotherapy and radiotherapy given as part of the stem cell transplant process. This method is not only available to younger patients who were too sick to have the full blown version but more importantly the reduced intensity approach has made it possible for Wilson and his team to treat older patients who were once largely excluded.

Today three quarters of all allogeneic or donor transplants are now done with this new method called reduced intensity conditioning. If we didnt have this method at our disposal it means that the vast majority of patients with haematological malignancies would not have this treatment optionwhichfor many cancers, is the only means of cure,explains Wilson.

Long before he began his journey to become a doctor and specialist, Wilson held several leadership positions as a pupil at Presentation College. He was head college prefect and sang in the school choir and was also platoon sergeant (Cadets). He learned to play the steelpan and was also actively involved in many sports organisations. He went on to study medicine at the University of the West Indies St Augustine and at UWI Mona, Jamaica. Wilson practised internal medicine at the San Fernando General Hospital before migrating to the UK in 1991.

There was one particular patient who motivated Wilson to specialise in haematology. At that time there was only one trained haematologist - the late Dr Waveney Charles serving T&T. The patient presented with a rare condition aplastic anaemia where the bone marrow shuts down. Wilson communicated with Charles about possible treatment options. But the patient wasnt suitable for any of the options which were available, instead he was given supportive care.

He did survive for about five years which was a feat in itself given that without proper treatment someone with severe aplastic anaemia would have a life expectancy of six to 18 months. He was young, mischievous, playful. Not being able to offer him what he needed best stirred in me a desire to do haematology, I remember saying to myself I must learn how to treat this condition and I must be able to do transplantation, so I credit my decision to do haematology and transplantation in particular to this young man who entered my life so many years ago,he says.

Wilson once had a dream of starting a stem cell transplant unit in the Caribbean but those plans never materialised for a number of reasons. There would need to be a combination of qualified physicians, infrastructural adjustments and support services to make it possible to do it safely but it is within reach if there is sufficient appetite to do it, he says.

The consultant haematologist has not forgotten his roots, over the years he has visited Trinidad at different intervals. He would embrace the opportunity to repay some of the investment that was made in him many years ago when he began his career in medicine.

Im always open to the possibility of helping the haematology community particularly with regards to haematological malignancy where I would be most equipped to make a contribution, he says.

Read this article:
Covid-19 and the blood - Trinidad & Tobago Express Newspapers